RE:RE:RE:RE:ONCY announces Pelareorep ≥50% ORR & mPFS Improvements Of particular note is that pelareorep (monotherapy) in combination with paclitaxel (cohort 2) resulted in a near tripling of confirmed overall response rate (ORR), a surrogate endpoint (biomarker) that could prompt the filing of an accelerated approval, given that advanced/metastatic HR+/HER2 (-) negative breast cancer is the most common cancer diagnosed in women and is still a cancer with an unmet treatment need.
Hormone receptor positive (HR+) and HER2 negative (HER2−) breast cancers account for at least 60% to 70% of all breast cancer cases. They usually metastasize to lymph nodes, bones, liver, lungs, and brain.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188964/